HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


After At-Home Diagnostics Got Boost From COVID, FTC Shows False Claims Didn’t End With Pandemic

Executive Summary

FTC and California Attorney General offer CRI Genetics LLC as exhibit A for making good on promised deliverables for DNA-based ancestry and information reports.

You may also be interested in...

Expected Spread Of US OTC Diagnostics Could Change Consumers’ Health Care Behaviors

Diagnostics platform provider Ash Wellness expects at-home test providers can help improve consumers’ long-term health care outcomes with follow-up and ongoing communications for users of their products, influencing them to change behaviors.

FTC ‘Dark Patterns' Enforcement Policy Darkens Public Input On Rule, Commissioner Wilson Argues

Wilson’s dissenting statement isn’t first time she's disagreed with Democrat majority on the five-seat commission after four years of a Republican majority. Her statement made clear her argument the commission has over-stepped its authorities more than once.

OTC Diagnostics Forecast: Growing With Pandemic But High Bar For Approval Could Slow Spread

Sample-collection kit and testing firms acknowledge regulatory approval for OTC sales can be as complicated as the technology behind their products. But consumers have OTC access to numerous at-home collection kits for tests for indications of diseases or medical conditions as well as for genealogy. Kits approved for testing for influenzas or other infections also should become available OTC, say industry stakeholders.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts